Dashboard PDUFA PDUFA History Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free public preview Track SNDX with free AI briefings, catalyst countdowns, and dilution alerts.

SNDX — Syndax Pharmaceuticals Inc

FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.

$336.5M Cash on Hand

25mo Cash Runway

25.8% Short Interest

🧪 Upcoming Trial Catalysts

2026-09-01 · Phase 2 — Active Trial — MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (
2026-10-01 · Phase 1 — Recruiting — Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With
2026-12-01 · Phase 1, Phase 2 — Recruiting — A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613
2026-12-01 · Phase 2 — Recruiting — A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation
2026-12-30 · Phase 1, Phase 2 — Recruiting — A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of B
2027-02-01 · Phase 1 — Active Trial — A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute

📊 Drug Pipeline

Drug	Indication	Phase	Status
Intensive Chemotherapy Regimen	Acute Myeloid Leukemias	PHASE3	RECRUITING
Nivolumab	Metastatic Cholangiocarcinoma	PHASE2	COMPLETED
Interleukin-2	Renal Cell Carcinoma	PHASE2	ACTIVE_NOT_RECRUITING
Erlotinib	Non Small Cell Lung Cancer	PHASE2	TERMINATED
Entinostat	Breast Cancer	PHASE2	COMPLETED
Durvalumab	Unresectable Intrahepatic Cholangiocarcinoma	PHASE2	COMPLETED
Ipilimumab	Renal Cell Carcinoma	PHASE2	TERMINATED
CC-486 300	Non-Small Cell Lung Cancer	PHASE2	COMPLETED
Azacitidine	Non-Small Cell Lung Cancer	PHASE2	COMPLETED
SNDX-6352	Unresectable Intrahepatic Cholangiocarcinoma	PHASE2	COMPLETED

💰 Cash Runway & Dilution Risk

SNDX holds $336.5M in cash and burns about $40.3M/quarter from operations, giving an estimated runway of 25 months. A recent offering filing was detected — dilution watch.

Source: SEC EDGAR XBRL (operating cash flow). Get dilution alerts for SNDX free →

📈 Recent Insider Activity (Form 4)

Date	Insider	Type	Value
2026-07-09	Metzger Michael A	Purchase	$3.3M
2026-07-09	Metzger Michael A	Sale	$11.8M
2026-07-09	Metzger Michael A	Purchase	$0
2026-06-12	Botwood Nicholas A.J.	Purchase	$1.3M
2026-06-12	Botwood Nicholas A.J.	Purchase	$1.3M

📅 Past FDA Decisions & Stock Reactions

Date	Drug	Type	Run-up 30d	Decision 1d	After 5d
2025-10-25	—	sNDA	-10%	-3.1%	+1.3%

Browse all historical PDUFA outcomes →

Get the full SNDX picture

A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for SNDX and 2 more tickers of your choice.

Create Free Account →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z